T cell injection targeting CD19 chimeric antigen receptor

BIOLOGICAL2 trials

Sponsors

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Conditions

Idiopathic Inflammatory MyopathiesIgG4 Related DiseaseImmune ThrombocytopeniaPrimary Biliary CholangitisPrimary Sjögren SyndromeRheumatoid ArthritisSjogren's SyndromeSystemic Lupus Erythematosus

Early Phase 1

Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Not yet recruitingNCT06417398

PersonGen BioTherapeutics (Suzhou) Co., Ltd.Idiopathic Inflammatory Myopathies, Immune Thrombocytopenia, Primary Biliary Cholangitis +4

Start: 2024-05-14End: 2025-05-01Target: 10Updated: 2024-05-16

Unknown Phase

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

RecruitingNCT06361745

PersonGen BioTherapeutics (Suzhou) Co., Ltd.Idiopathic Inflammatory Myopathies, IgG4 Related Disease, Primary Sjögren Syndrome +2

Start: 2024-04-02End: 2025-03-01Target: 10Updated: 2024-04-15